Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why
Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why
No new safety signals were reported.On Wednesday, Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced a preplanned interim analysis of the Reliance II Phase 3 study.
Relmada Therapeutics公司（納斯達克股票代碼：RLMD）週三宣佈對Reliance II第3期研究進行預先計劃的中期分析。
Reliance II is designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder (MDD), to be used in combination with other approved anti-depressants.
Reliance II旨在評估REL-1017作爲重性抑鬱症（MDD）的輔助治療，與其他已批准的抗抑鬱藥物聯合使用。
The Independent Data Monitoring Committee (DMC) analysis indicated that the Reliance II Phase 3 study is futile and unlikely to meet the primary efficacy endpoint with statistical significance.
獨立的數據監測委員會（DMC）分析表明，Reliance II第3期研究是徒勞的，不太可能以統計學顯著性達到主要療效終點。
No new safety signals were reported.
沒有報告新的安全信號。
"We are disappointed with the outcome of this interim analysis," said Sergio Traversa, Chief Executive Officer of Relmada. "Based on these results, Relmada will evaluate the full dataset to determine next steps for the REL-1017 program. The Company will continue to advance the Phase 1 study of REL-P11, an investigational agent for the treatment of metabolic disease, currently in a Phase 1 first-in-human study. We are grateful to the investigative sites and patients who participated in the REL-1017 program."
"我們對這次中期分析的結果感到失望，" Relmada首席執行官Sergio Traversa表示。"基於這些結果，Relmada將評估完整數據集，以確定REL-1017計劃的下一步措施。公司將繼續推進REL-P11的第1期研究，這是一種用於治療代謝疾病的實驗性藥物，目前正處於第1期人體首次研究階段。我們感謝參與REL-1017計劃的研究地點和患者。"
In July 2021, Relmada acquired the development and commercial rights to a novel psilocybin and derivatives program. Psilocybin has neuroplastogen effects that have the potential to ameliorate neurodegenerative conditions.
2021年7月，Relmada收購了一項關於新型哲學家賽洛西賓和衍生物計劃的開發和商業化權利。哲學家賽洛西賓具有可能改善神經變性疾病的神經可塑性效應。
Relmada identified the potential to use low-dose psilocybin to treat metabolic diseases and published the data at the American Society for the Study of Liver Disease.
Relmada確定了使用低劑量哲學家賽洛西賓治療代謝性疾病的潛力，並在美國肝病研究學會上發佈了數據。
Last year, Relmada Therapeutics released efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3 trial (Study 310) of REL-1017 in patients with Major Depressive Disorder (MDD).
去年，Relmada Therapeutics發佈了關於重性抑鬱症患者（204名患者）的de novo（或新接受治療）患者的療效結果以及所有受試者（627名患者）的安全性結果，這是REL-1017在患有重性抑鬱症（MDD）的患者中的第3期試驗（研究310）。
Patients treated daily with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment.
接受REL-1017治療的患者在長達一年的治療中，經歷了快速、臨床意義顯著且持續改善的抑鬱症狀和相關的功能障礙。
In November, Relmada Therapeutics initiated dosing in a Phase 1 SAD study of REL-P11, an investigational agent for metabolic disease. Phase 2a proof-of-concept study is expected to begin in the first half of 2025.
relmada therapeutics在十一月份開始對REL-P11進行一項SAD第一階段研究的給藥，這是一種用於治療代謝疾病的研究劑。預計2025年上半年開始進行第2a階段的概念驗證研究。
Price Action: RLMD stock is down 75.4% at $0.68 at last check Wednesday.
股價走勢：週三最後一次查看時，RLMD股價下跌了75.4%，報0.68美元。
- Edwards Lifesciences Outlines Vision For Growth At Investor Conference
- 愛德華生命科學在投資者會議上概述了增長願景
Photo via Shutterstock
圖片來自shutterstock
譯文內容由第三人軟體翻譯。
